Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side effects of its obesity and diabetes drugs.

Shares of Eli Lilly plunged after the drug maker reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster. The pill helped people ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...